Compare Axogen Inc (AXGN) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Jumia Technologies AG - ADR — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Jumia Technologies AG - ADR trades at $6.45 (market cap $719.58M). The key difference: Axogen Inc is far larger — about 3.6× Jumia Technologies AG - ADR's market cap, and Axogen Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| AXGN | JMIA | |
|---|---|---|
Market Cap | $2.61B | $719.58M |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $14.60 |
52-Week Low | $14.16 | $5.69 |
Enterprise Value | $2.52B | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
JMIA trades at $6.325, up 5.42% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights progress toward Q4 2026 breakeven and a $50 million capital raise.
The outlook remains speculative with persistent losses and high valuation ratios like P/B of 55.05, but analyst consensus is bullish with 71% buy ratings. Key risks include cash burn and competitive pressures, while catalysts include continued operating leverage and expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
